TG Therapeutics, Inc. (TGTX) Bundle
Ever wondered about the story behind TG Therapeutics, Inc. (TGTX), a biopharmaceutical company making waves in the treatment of B-cell diseases? With a strong focus on developing novel treatments, particularly for multiple sclerosis, TG Therapeutics has seen impressive growth, reporting full-year 2024 net product revenue of $313.7 million, a substantial increase from $92.0 million in 2023. Want to know how they achieved this and what their plans are for the future? Keep reading to discover the history, ownership structure, mission, and business model that drive this innovative company.
TG Therapeutics, Inc. (TGTX) History
TG Therapeutics, Inc.'s Founding Timeline
Year established
TG Therapeutics, Inc. was established in 2011.
Original location
The company is headquartered in Parsippany, New Jersey.
Founding team members
The information available does not specify the complete list of the founding team members. However, Michael S. Weiss is a prominent figure as the Co-Founder, Executive Chairman, and Chief Executive Officer.
Initial capital/funding
Details regarding the initial capital or funding for TG Therapeutics' establishment are not explicitly available in the provided search results.
TG Therapeutics, Inc.'s Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2014 | Acquisition of LFB USA, Inc. | Expanded TG Therapeutics' portfolio with a Phase 3-ready anti-CD20 monoclonal antibody, ublituximab (TG-1101). |
| 2017 | Filing of U2 combination therapy NDA/MAA | Submitted a New Drug Application (NDA) and Marketing Authorization Application (MAA) for the combination of ublituximab and umbralisib (U2), marking a significant step toward potential regulatory approval. |
| 2018 | Presentation of positive data from the UNITY-CLL Phase 3 trial | Showed that the U2 combination significantly improved progression-free survival in patients with chronic lymphocytic leukemia (CLL). |
| 2021 | FDA approval of Ukoniq (umbralisib) | Ukoniq received accelerated approval for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy. |
| 2022 | Withdrawal of Ukoniq (umbralisib) | TG Therapeutics voluntarily withdrew Ukoniq due to concerns about an increased risk of death in patients treated with the drug. |
| 2023 | FDA Approval of Briumvi (ublituximab-xiiy) | Briumvi was approved for the treatment of relapsing forms of multiple sclerosis (RMS), marking a significant advancement in the company's pipeline and a new treatment option for patients. |
TG Therapeutics, Inc.'s Transformative Moments
- 2014: Acquisition of LFB USA: This acquisition was transformative as it brought ublituximab into the company's pipeline, which later became a key asset.
- 2021: Initial Approval of Ukoniq: While Ukoniq was later withdrawn, its initial approval represented a milestone, demonstrating the company's ability to bring a drug to market.
- 2023: Approval of Briumvi: The approval of Briumvi for relapsing forms of multiple sclerosis (RMS) is perhaps the most transformative moment. It signified a major success, providing a new revenue stream and validating the company's research and development efforts.
- Voluntary Withdrawal of Ukoniq in 2022: Though a setback, the decision to withdraw Ukoniq demonstrated the company's commitment to patient safety and ethical responsibility.
To gain more insights into the company's guiding principles, explore: Mission Statement, Vision, & Core Values of TG Therapeutics, Inc. (TGTX).
TG Therapeutics, Inc. (TGTX) Ownership Structure
TG Therapeutics, Inc. features a mixed ownership structure, comprising institutional investors, individual shareholders, and company insiders, influencing its strategic decisions and corporate governance.
TG Therapeutics, Inc.'s Current Status
TG Therapeutics, Inc. is a publicly traded company, meaning its shares are available for purchase on stock exchanges by the general public. This allows the company to raise capital through the issuance of stock and provides liquidity for its investors.
TG Therapeutics, Inc.'s Ownership Breakdown
Here is a breakdown of TG Therapeutics, Inc.'s ownership structure:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Owners | 77.87% | Includes investment firms, mutual funds, and other institutions. Top institutional holders include BlackRock Fund Advisors, Vanguard, and State Street. |
| Individual Insiders | 0.78% | Shares held by company executives and board members. |
| Retail Investors | Remaining percentage | General public investors who hold a smaller percentage of the company's shares. |
TG Therapeutics, Inc.'s Leadership
The leadership team of TG Therapeutics, Inc. plays a crucial role in guiding the company's strategic direction and operations. Key members of the leadership team as of April 2025 include:
- Michael S. Weiss: Chairman and Chief Executive Officer
- Sean A. Power: Chief Financial Officer
These individuals, along with other key executives, are responsible for the company's day-to-day operations, financial performance, and long-term strategic goals.
Further insights into TG Therapeutics, Inc. can be found here: Exploring TG Therapeutics, Inc. (TGTX) Investor Profile: Who’s Buying and Why?
TG Therapeutics, Inc. (TGTX) Mission and Values
TG Therapeutics is dedicated to acquiring, developing, and commercializing innovative treatments for B-cell malignancies and autoimmune diseases, driven by a commitment to improving patient outcomes and addressing unmet medical needs.
TG Therapeutics' Core Purpose
Official mission statement
TG Therapeutics does not appear to have a formal, publicly declared mission statement. However, information from their website and press releases indicates the company is dedicated to:
- Developing and delivering innovative medicines for patients with B-cell malignancies and autoimmune diseases.
- Focusing on areas of unmet medical need to improve patient outcomes.
- Advancing research and development efforts to bring new treatment options to market.
Vision statement
While a specific vision statement isn't formally published, TG Therapeutics' actions and communications suggest a vision focused on:
- Becoming a leader in the development and commercialization of therapies for B-cell malignancies and autoimmune conditions.
- Transforming the treatment landscape for patients through scientific innovation.
- Expanding their portfolio of novel therapies to address a wider range of diseases.
Company slogan/tagline
TG Therapeutics does not have an official slogan or tagline that is widely publicized. Instead, they focus on communicating their dedication to innovation and patient care through their corporate activities and product development. To gain more in-depth knowledge about TG Therapeutics, explore this informative resource: Exploring TG Therapeutics, Inc. (TGTX) Investor Profile: Who’s Buying and Why?
TG Therapeutics, Inc. (TGTX) How It Works
TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
TG Therapeutics, Inc.'s Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| BRIUMVI (ublituximab-xiiy) | Relapsing forms of multiple sclerosis (RMS) |
|
| UKONIQ (umbralisib) | Adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen; and adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy |
|
TG Therapeutics, Inc.'s Operational Framework
TG Therapeutics operates through a focused approach to drug development and commercialization. Key aspects of their operational framework include:
- Research and Development: Investing in innovative research to identify and develop novel therapies for B-cell malignancies and autoimmune diseases.
- Clinical Trials: Conducting rigorous clinical trials to evaluate the safety and efficacy of their drug candidates.
- Regulatory Approval: Seeking regulatory approvals from agencies like the FDA to bring their products to market.
- Commercialization: Building a commercial infrastructure to market and sell their approved products, including a sales force and marketing team.
- Partnerships and Collaborations: Collaborating with other companies and research institutions to expand their pipeline and capabilities.
TG Therapeutics focuses on therapies that target specific pathways involved in B-cell malignancies and autoimmune diseases. This targeted approach aims to improve patient outcomes while minimizing side effects.
TG Therapeutics, Inc.'s Strategic Advantages
TG Therapeutics, Inc. has several strategic advantages that contribute to its success in the biopharmaceutical industry:
- Targeted Therapies: Focus on developing therapies that specifically target B-cell malignancies and autoimmune diseases, potentially leading to more effective treatments.
- Innovative Pipeline: A pipeline of novel drug candidates with the potential to address unmet medical needs.
- Experienced Management Team: A management team with experience in drug development and commercialization.
- Strategic Partnerships: Collaborations with other companies and research institutions to expand their capabilities and pipeline.
To gain more insights into the company's goals, explore: Mission Statement, Vision, & Core Values of TG Therapeutics, Inc. (TGTX).
TG Therapeutics, Inc. (TGTX) How It Makes Money
TG Therapeutics, Inc. primarily generates revenue through the commercialization of its pharmaceutical products, particularly Briumvi, which is used in the treatment of multiple sclerosis (MS). Licensing agreements and collaborations with other pharmaceutical companies also contribute to their income.
TG Therapeutics, Inc. Revenue Breakdown
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Briumvi Sales | >95% | Increasing |
| Collaboration and Licensing Agreements | <5% | Variable |
TG Therapeutics, Inc. Business Economics
The economic model of TG Therapeutics is centered on the development, manufacturing, and marketing of specialty drugs. Key aspects of their business economics include:
- Pricing Strategy: TG Therapeutics prices its drugs, such as Briumvi, based on the value they provide in treating specific conditions like multiple sclerosis. The pricing considers factors like efficacy, competitive landscape, and cost of development.
- Cost of Goods Sold (COGS): This includes the direct costs associated with manufacturing Briumvi, impacting gross margins.
- R&D Expenses: A significant portion of their expenses is allocated to research and development, crucial for developing new treatments and expanding the applications of existing drugs.
- SG&A Expenses: Selling, general, and administrative expenses cover marketing, sales, and administrative functions necessary to commercialize and support their products.
- Partnerships and Licensing: Strategic alliances can provide upfront payments, milestone payments, and royalties, influencing overall profitability.
TG Therapeutics, Inc. Financial Performance
TG Therapeutics' financial performance can be assessed through the following points:
- Revenue Growth: Primarily driven by the sales of Briumvi, revenue growth indicates the market acceptance and penetration of their main product. For example, in 2023, Briumvi showed substantial revenue growth, becoming a key revenue driver.
- Gross Margin: This metric reflects the efficiency of TG Therapeutics' production and pricing strategies. It is calculated as revenue less COGS, divided by revenue.
- Operating Expenses: Monitoring R&D and SG&A expenses as a percentage of revenue provides insights into the company's operational efficiency and investment in future growth.
- Net Income/Loss: This is a critical indicator of overall profitability, influenced by revenue, costs, and other income/expenses.
- Cash Flow: Analyzing cash flow from operations, investing, and financing activities helps evaluate the company’s liquidity and financial stability.
For an in-depth analysis, you might find this resource helpful: Breaking Down TG Therapeutics, Inc. (TGTX) Financial Health: Key Insights for Investors
TG Therapeutics, Inc. (TGTX) Market Position & Future Outlook
TG Therapeutics is navigating a competitive landscape in the pharmaceutical industry, particularly within the areas of hematological malignancies and autoimmune diseases. Their future success hinges on the continued adoption of their approved therapies, strategic pipeline development, and effective management of market challenges.
Competitive Landscape
The following table provides a snapshot of TG Therapeutics' market position relative to its competitors:
| Company | Market Share, % | Key Advantage |
|---|---|---|
| TG Therapeutics, Inc. | Approx. 2-3% (in relevant market segments) | Specialized focus on specific patient populations; novel therapies. |
| Roche | Approx. 25-30% (in oncology and immunology) | Extensive portfolio; established global presence. |
| Novartis | Approx. 15-20% (in oncology and immunology) | Diverse product offerings; strong research and development capabilities. |
Opportunities & Challenges
TG Therapeutics faces a mix of opportunities and risks that will shape its trajectory in the coming years:
| Opportunities | Risks |
|---|---|
| Expansion of approved therapies into new indications, potentially increasing market reach and revenue. | Competition from established pharmaceutical giants with greater resources and broader market access. |
| Strategic partnerships and collaborations to accelerate drug development and commercialization efforts. | Regulatory hurdles and potential delays in obtaining approvals for pipeline products. |
| Advancements in research and development leading to innovative therapies for unmet medical needs. | Uncertainties surrounding market access and reimbursement for new therapies. |
Industry Position
TG Therapeutics holds a unique position within the pharmaceutical industry, characterized by:
- A focus on developing and commercializing therapies for specific unmet needs in hematological malignancies and autoimmune diseases.
- A pipeline of novel drug candidates with the potential to address significant gaps in treatment options.
- A commitment to innovation and personalized medicine, tailoring treatments to individual patient characteristics.
For more insights into the values that drive TG Therapeutics, explore: Mission Statement, Vision, & Core Values of TG Therapeutics, Inc. (TGTX).
TG Therapeutics, Inc. (TGTX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.